XSES
8K7
Market cap37mUSD
Sep 16, Last price
0.08SGD
1D
2.67%
1Q
-6.10%
Jan 2017
-18.95%
IPO
5.00%
Name
UG Healthcare Corporation Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
UG Healthcare Corporation Limited, an investment holding company established in Singapore in 1989, primarily engages in the manufacturing and worldwide distribution of disposable gloves. Its business is structured across three main segments: Latex Examination Gloves, Nitrile Examination Gloves, and a category for Other Ancillary Products. The company's offerings include both latex examination gloves, available in single and double chlorinated polymer-coated varieties, as well as nitrile examination gloves. Additionally, it supplies a range of supplementary items like surgical gloves, vinyl and cleanroom disposable gloves, face masks, various other medical disposables, and protective shoe covers. The firm also extends its expertise through business and management consultancy services. Its products serve diverse sectors such as healthcare, food and beverage, industrial and high-technology manufacturing, automotive, research and development, and the beauty industry. Operating under its "Unigloves" brand name, the corporation reaches customers across Malaysia, Europe, North America, South America, Africa, and the broader Asian market.
Key people
Wah Pung Yip
Non-Executive Independent Chairman of the Board · since 2014
Jun Yih Lee
Finance Director · since 2019
Lee Jun Yih
Executive Director · since 2014
Jun Linn Lee
Executive Director · since 2014
Keck Keong Lee
Chief Executive Officer, Executive Director · since 2016
See Keong Wong
Executive Director · since 2014
Beng Chee Ang
Head of Administration
Pek Wee Wong
Head of Manufacturing
Independent Director · since 2014
Independent Director · since 2014
IPO date
Dec 08, 2014
Employees
1,076
Domiciled in
MY
Incorporated in
SG
Valuation
Title SGD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026‑06 | 2025‑06 | 2024‑06 | 2023‑06 | 2022‑06 | 2021‑06 | 2020‑06 | 2019‑06 | 2018‑06 | 2017‑06 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||